EMA and HMA Mark a Key Step with 1st AI Observatory Report
The European Medicines Agency (EMA) recently shared a post on LinkedIn:
”The first AI Observatory report by EMA and the Heads of Medicines Agencies (HMA) summarises the experience gained in hashtag Artificial Intelligence across the EU medicines regulatory network in 2024. The report includes a high-level horizon scanning to identify gaps, challenges and opportunities for integrating AI in medicines regulation.
Key observations:
- AI is increasingly being used through the medicine’s lifecycle, especially in the pre-authorisation stage, with a broad scope of applications to gain insights and support decision making
- By 2024, EMA had been involved in 7 processes to qualify AI tools for medicine development and in 4 scientific advice procedures related to AI
- The network plans to use AI to automate processes and enhance systems or personal productivity – 27 AI tools were reported in 2024, of which 14 were from national agencies.
The AI Observatory was launched as part of the multi-annual AI workplan by the HMA-EMA Network Data Steering Group. The aim is to leverage safe and responsible use of AI for the benefit of public and animal health in the EU.”
The EMA and Heads of Medicines Agencies (HMA) have released their first AI Observatory report, summarizing AI use in the EU medicines regulatory network in 2024.
AI is increasingly applied in medicine development, especially before authorisation, with EMA engaging in 7 AI qualification and 4 scientific advice procedures last year.
The network reported 27 AI tools, including 14 from national agencies, to automate processes and enhance productivity.
The Observatory, part of the HMA-EMA AI workplan, aims to ensure the safe and responsible use of AI in medicines regulation.
Hemostasis Today: Your Daily Brief on Key Medical Developments.
-
Sep 12, 2025, 06:39Chokri Ben Lamine: Approach to Intra-Operative Bleeding in G6P Deficiency – Key Causes and Management
-
Sep 11, 2025, 08:33Alfonso J. Tafur Shares VascuLearn’s Free Virtual Support Groups This Fall for Patients and Providers
-
Sep 10, 2025, 23:00Blood Vessels, Thrombosis and Hemostasis - Blood VTH and Blood Neoplasia: Now Indexed in PubMed!
-
Sep 10, 2025, 13:00Shivani Modi Presents 7 Posters at SOHO 2025: From AI to Hematologic Emergencies
-
Sep 10, 2025, 09:27Deep Vein Thrombosis (DVT) Explained in One Slide: Causes, Symptoms, Diagnosis and Treatment
-
Sep 12, 2025, 06:21Flora Peyvandi on Why Plasminogen Activation Is Not Required to Prevent Venous Thrombosis
-
Sep 12, 2025, 03:38Haematologica Early View: Omid Seidizadeh Explores Genetics Behind Clinical Variability in Type 2 VWD
-
Sep 11, 2025, 15:03Rapid ADAMTS13 Assays: A Key Milestone in the 100 Years of Innvoation in TTP Diagnosis - Silvio Castagni
-
Sep 11, 2025, 13:55Transplantation-Mediated Alloimmune Thrombocytopenia: Mostafa Faisal Mohammed Saleh Presents a Rare Case
-
Sep 10, 2025, 22:34Nicolas Gendron on The Emerging Role of CLIA in The Diagnosis Strategy for HIT
-
Sep 9, 2025, 20:15Linking a Single Dominant Antibody to HIT: A Novel Study Led by Ishac Nazy, Donald Arnold, and John G. Kelton
-
Sep 8, 2025, 14:24Von Willebrand Factor as a Therapeutic Target․ From Development to Clinical Application
-
Sep 8, 2025, 02:35Reza Shojaei on the Real Worth of Hemoglobin Oxygen Carriers – HBOCs
-
Sep 7, 2025, 14:16Mary Kiige: Biological Hemoglobin Oxygen Carrier as a Lifesaving Oxygen Bridge
-
Sep 7, 2025, 14:13Breakthrough in Blood: Cécile Denis and INSERM Team Develop Nanobody Therapy for Type 1 VWD
-
Sep 11, 2025, 15:27Postpartum Haemorrhage: In Kenya, More than 120 Mothers Die for Every 100,000 Live Births
-
Sep 11, 2025, 08:08Al-Ola A Abdallah on MGUS-Related Bleeding Disorders
-
Sep 10, 2025, 19:32Denis Brutus Oduor: Call for Altruism in Blood Donation in Nairobi
-
Sep 9, 2025, 10:34James Douketis Receives the 2025 Distinguished Service Award in General Internal Medicine!
-
Sep 9, 2025, 08:07Hemophilia Federation of America Launches ‘Blood Brothers’ Podcast for Men With Bleeding Disorders